{"id":86,"date":"2023-02-13T10:00:00","date_gmt":"2023-02-13T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=86"},"modified":"2025-09-08T00:30:08","modified_gmt":"2025-09-08T00:30:08","slug":"china-bd-deal-2023-hengrui-and-treeline-enters-a-706-million-usd-license-on-ezh2-inhibitor-shr2554","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2023\/86.html","title":{"rendered":"[China BD 2023] Hengrui and Treeline \u00a0enters a 706 million USD license on EZH2 inhibitor SHR2554 (TLN-254)"},"content":{"rendered":"\n<p>Announced Date: 2023-02-12 (February 12, 2023)<\/p>\n\n\n\n<p>Asset Name: SHR2554 (TLN-254)<\/p>\n\n\n\n<p>Licensor: Hengrui Pharmaceuticals Co. Ltd (China)<\/p>\n\n\n\n<p>Licensee (Buyer): Treeline Biosciences, Inc. (US\uff09<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Small Molecule<\/p>\n\n\n\n<p>Asset Target: EZH2 inhibitor (Enhancer of Zeste Homolog 2)<\/p>\n\n\n\n<p>Potential Indication:  lymphoma <\/p>\n\n\n\n<p>Current Stage: Phase I, China<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>Treeline will be granted worldwide exclusive rights to the EZH2 inhibitor SHR2554, except for greater China  (Mainland China, Hong Kong, Macau and Taiwan).<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Upfront payment of&nbsp;$11 million,<\/p>\n\n\n\n<p>Development and regulatory milestone payments up to &nbsp;$45 million,<\/p>\n\n\n\n<p>Sales milestone payments  up to $650 million,<\/p>\n\n\n\n<p>Total up to $706 million.<\/p>\n\n\n\n<p>Royalties on net sales, &nbsp;tiered (10%-12.5%).<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link: <\/p>\n\n\n\n<p><a href=\"https:\/\/static.sse.com.cn\/disclosure\/listedinfo\/announcement\/c\/new\/2023-02-13\/600276_20230213_63RJ.pdf\">https:\/\/static.sse.com.cn\/disclosure\/listedinfo\/announcement\/c\/new\/2023-02-13\/600276_20230213_63RJ.pdf<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2023-02-12 (February 12, 2023) Asset Name: SHR2554 (TLN-254) Licensor: Hengrui Pharmaceuticals Co. Ltd (China) &hellip; <a title=\"[China BD 2023] Hengrui and Treeline \u00a0enters a 706 million USD license on EZH2 inhibitor SHR2554 (TLN-254)\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2023\/86.html\"><span class=\"screen-reader-text\">[China BD 2023] Hengrui and Treeline \u00a0enters a 706 million USD license on EZH2 inhibitor SHR2554 (TLN-254)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-86","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/86","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=86"}],"version-history":[{"count":4,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/86\/revisions"}],"predecessor-version":[{"id":244,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/86\/revisions\/244"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=86"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=86"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=86"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}